Hairy Cell Leukemia (HCL) Completed Phase 1 / 2 Trials for Obinutuzumab (DB08935)

Also known as: Hairy-cell Leukemia / Hairy cell leukaemia / Hairy Cell Leukemia / Leukemia, Hairy Cell / Leukemic reticuloendotheliosis / Hairy cell leukemia (disorder) / Hairy cell leukemia (morphologic abnormality) / Hairy cell leukemia with failed remission / Leukemic reticuloendotheliosis -RETIRED- / Leukaemic reticuloendotheliosis / Leukemic reticuloendotheliosis NOS (disorder) / Leukemic reticuloendotheliosis of unspecified sites (disorder) / [M]Leukaemic reticuloendotheliosis

IndicationStatusPhase
DBCOND0046776 (Hairy Cell Leukemia (HCL))Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03010358Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin LymphomaTreatment